Abstract
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer in the world. Most patients are diagnosed in advanced stages of the disease, with unsatisfactory survival rates. In locally advanced and unresectable HNSCC standard treatment in ICESP is cisplatin based chemoradiotherapy (QRT). The discovery of markers that may indicate the benefit of QRT regimens, taking in…